159 related articles for article (PubMed ID: 12034846)
1. Acridine-modified, clamp-forming antisense oligonucleotides synergize with cisplatin to inhibit c-Myc expression and B16-F0 tumor progression.
Stewart DA; Xu X; Thomas SD; Miller DM
Nucleic Acids Res; 2002 Jun; 30(11):2565-74. PubMed ID: 12034846
[TBL] [Abstract][Full Text] [Related]
2. Psoralen-modified clamp-forming antisense oligonucleotides reduce cellular c-Myc protein expression and B16-F0 proliferation.
Stewart DA; Thomas SD; Mayfield CA; Miller DM
Nucleic Acids Res; 2001 Oct; 29(19):4052-61. PubMed ID: 11574688
[TBL] [Abstract][Full Text] [Related]
3. Antitumor effect of c-myc antisense phosphorothioate oligodeoxynucleotides on human melanoma cells in vitro and and in mice.
Leonetti C; D'Agnano I; Lozupone F; Valentini A; Geiser T; Zon G; Calabretta B; Citro G C; Zupi G
J Natl Cancer Inst; 1996 Apr; 88(7):419-29. PubMed ID: 8618233
[TBL] [Abstract][Full Text] [Related]
4. Increase of cisplatin sensitivity by c-myc antisense oligodeoxynucleotides in a human metastatic melanoma inherently resistant to cisplatin.
Leonetti C; Biroccio A; Candiloro A; Citro G; Fornari C; Mottolese M; Del Bufalo D; Zupi G
Clin Cancer Res; 1999 Sep; 5(9):2588-95. PubMed ID: 10499637
[TBL] [Abstract][Full Text] [Related]
5. c-myc antisense oligodeoxynucleotides enhance the efficacy of cisplatin in melanoma chemotherapy in vitro and in nude mice.
Citro G; D'Agnano I; Leonetti C; Perini R; Bucci B; Zon G; Calabretta B; Zupi G
Cancer Res; 1998 Jan; 58(2):283-9. PubMed ID: 9443406
[TBL] [Abstract][Full Text] [Related]
6. Antiproliferative effect of c-myc antisense phosphorothioate oligodeoxynucleotides in malignant glioma cells.
Broaddus WC; Chen ZJ; Prabhu SS; Loudon WG; Gillies GT; Phillips LL; Fillmore H
Neurosurgery; 1997 Oct; 41(4):908-15. PubMed ID: 9316053
[TBL] [Abstract][Full Text] [Related]
7. Antitumor efficacy of bcl-2 and c-myc antisense oligonucleotides in combination with cisplatin in human melanoma xenografts: relevance of the administration sequence.
Zupi G; Scarsella M; Semple SC; Mottolese M; Natali PG; Leonetti C
Clin Cancer Res; 2005 Mar; 11(5):1990-8. PubMed ID: 15756025
[TBL] [Abstract][Full Text] [Related]
8. Growth inhibition of SK-MEL-30 human melanoma cells by antisense c-myc oligonucleotides delivered by poly(N-isopropylacrylamide)/ poly(ethyleneimine) copolymer.
Dinçer S; Oskay EK; Piskin AK; Zeybek ND; Pişkin E
J Tissue Eng Regen Med; 2010 Jun; 4(4):284-90. PubMed ID: 19967748
[TBL] [Abstract][Full Text] [Related]
9. Cationic lipids reduce time and dose of c-myc antisense oligodeoxynucleotides required to specifically inhibit Burkitt's lymphoma cell growth.
Williams SA; Chang L; Buzby JS; Suen Y; Cairo MS
Leukemia; 1996 Dec; 10(12):1980-9. PubMed ID: 8946941
[TBL] [Abstract][Full Text] [Related]
10. Inhibitory effects of antisense oligodeoxynucleotides targeting c-myc mRNA on smooth muscle cell proliferation and migration.
Biro S; Fu YM; Yu ZX; Epstein SE
Proc Natl Acad Sci U S A; 1993 Jan; 90(2):654-8. PubMed ID: 8421701
[TBL] [Abstract][Full Text] [Related]
11. Modulation of cellular functions in retroorbital fibroblasts using antisense oligonucleotides targeting the c-myc protooncogene.
Heufelder AE; Bahn RS
Invest Ophthalmol Vis Sci; 1995 Jun; 36(7):1420-32. PubMed ID: 7775120
[TBL] [Abstract][Full Text] [Related]
12. Encapsulation of c-myc antisense oligodeoxynucleotides in lipid particles improves antitumoral efficacy in vivo in a human melanoma line.
Leonetti C; Biroccio A; Benassi B; Stringaro A; Stoppacciaro A; Semple SC; Zupi G
Cancer Gene Ther; 2001 Jun; 8(6):459-68. PubMed ID: 11498766
[TBL] [Abstract][Full Text] [Related]
13. Folic acid-polylysine carrier improves efficacy of c-myc antisense oligodeoxynucleotides on human melanoma (M14) cells.
Ginobbi P; Geiser TA; Ombres D; Citro G
Anticancer Res; 1997; 17(1A):29-35. PubMed ID: 9066627
[TBL] [Abstract][Full Text] [Related]
14. Antisense oligodeoxynucleotide combination therapy of primary chronic myelogenous leukemia blast crisis in SCID mice.
Skorski T; Nieborowska-Skorska M; Wlodarski P; Zon G; Iozzo RV; Calabretta B
Blood; 1996 Aug; 88(3):1005-12. PubMed ID: 8704208
[TBL] [Abstract][Full Text] [Related]
15. Electroporation increases antitumoral efficacy of the bcl-2 antisense G3139 and chemotherapy in a human melanoma xenograft.
Spugnini EP; Biroccio A; De Mori R; Scarsella M; D'Angelo C; Baldi A; Leonetti C
J Transl Med; 2011 Jul; 9():125. PubMed ID: 21798045
[TBL] [Abstract][Full Text] [Related]
16. Modification of the sensitivity to cisplatin with c-myc over-expression or down-regulation in colon cancer cells.
Funato T; Kozawa K; Kaku M; Sasaki T
Anticancer Drugs; 2001 Nov; 12(10):829-34. PubMed ID: 11707650
[TBL] [Abstract][Full Text] [Related]
17. Effects of phosphodiester and phosphorothioate antisense oligodeoxynucleotides on cell lines which overexpress c-myc: implications for the treatment of Burkitt's lymphoma.
Williams SA; Gillan ER; Knoppel E; Buzby JS; Suen Y; Cairo MS
Ann Oncol; 1997; 8 Suppl 1():25-30. PubMed ID: 9187425
[TBL] [Abstract][Full Text] [Related]
18. c-myc antisense oligonucleotides sensitize human colorectal cancer cells to chemotherapeutic drugs.
Abaza MS; Al-Saffar A; Al-Sawan S; Al-Attiyah R
Tumour Biol; 2008; 29(5):287-303. PubMed ID: 18802399
[TBL] [Abstract][Full Text] [Related]
19. A combination treatment of c-myc antisense DNA with all-trans-retinoic acid inhibits cell proliferation by downregulating c-myc expression in small cell lung cancer.
Akie K; Dosaka-Akita H; Murakami A; Kawakami Y
Antisense Nucleic Acid Drug Dev; 2000 Aug; 10(4):243-9. PubMed ID: 10984118
[TBL] [Abstract][Full Text] [Related]
20. Enhancement of sensitivity of urinary bladder tumor cells to cisplatin by c-myc antisense oligonucleotide.
Mizutani Y; Fukumoto M; Bonavida B; Yoshida O
Cancer; 1994 Nov; 74(9):2546-54. PubMed ID: 7923012
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]